[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346476-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346476-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unlocking-the-power-of-non-coding-rnas-toward-real-time-cancer-monitoring-in-precision-oncology","Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology","","Precision oncology tailors cancer treatment to individual molecular profiles, yet many patients still fail to benefit from current options. This review evaluates biomarkers, especially non-invasive liquid-biospy signals, that can guide more effective, adaptive strategies beyond circulating tumor DNA. It focuses on non-coding RNAs—microRNAs, long non-coding RNAs, and circular RNAs—because they remain stable across body fluids and dynamically reflect treatment effects. Packaged in extracellular vesicles or protein/lipid complexes, circulating ncRNAs originate from tumor and microenvironmental cells. The article argues for their value as longitudinal, real-time markers for therapy response, recurrence detection, and personalized management.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unlocking-the-power-of-non-coding-rnas-toward-real-time-cancer-monitoring-in-precision-oncology/346476/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unlocking-the-power-of-non-coding-rnas-toward-real-time-cancer-monitoring-in-precision-oncology/346476.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are non-coding RNAs considered promising biomarkers in precision oncology?","Question",{"text":63,"@type":64},"Non-coding RNAs such as microRNAs, long non-coding RNAs, and circular RNAs are highlighted because they are stable in body fluids and dynamically change in response to treatment. This supports their use as informative biomarkers for monitoring cancer over time.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do liquid biopsies improve therapeutic guidance compared with traditional approaches?",{"text":68,"@type":64},"The text emphasizes that biomarkers measurable in non-invasive liquid biopsies can enable more effective and dynamic therapeutic strategies. It contrasts the limitations of circulating tumor DNA in capturing tumor complexity with the broader biological insight provided by ncRNAs.",{"name":70,"@type":61,"acceptedAnswer":71},"What key characteristics must clinically useful biomarkers have?",{"text":72,"@type":64},"Clinically valuable biomarkers should be safe, easy, and cost-effective to measure, preferably non-invasively, with high sensitivity and high specificity. They should also show strong positive and negative predictive values for the intended outcome.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346476,1790145914,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Chang etal. Molecular Cancer (2026) 25:34 [https://doi.org/10.1186/s12943-025-02536-y](https://doi.org/10.1186/s12943-025-02536-y)  \nMolecular Cancer  \nREVIEW Open Access  \nUnlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology  \nManon Chang1†, Thomas Papazyan1,2†, Elvire Pons-Tostivint1,2† and Delphine Fradin1*†  \nAbstract  \nPrecision oncology has transformed cancer care by tailoring treatments to individual molecular profiles, but many patients still fail to benefit from current therapies. In this context, biomarkers, particularly those measurable in non-invasive liquid biopsies, offer a promising path toward more effective and dynamic therapeutic strategies. Traditionally, circulating tumor DNA (ctDNA) has guided therapeutic decisions, but its limitations in capturing tumor complexity are becoming increasingly apparent. Conversely, non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) are emerging as powerful biomarkers due to their stability in all body fluids and their dynamic regulation in response to treatment. Encapsulated in extracellular vesicles (EVs) or associated with protein/lipid complexes, circulating ncRNAs are released by both tumor and microenvironmental cells, offering a unique biological insight. This review highlights the unique potential of ncRNAs as longitudinal biomarkers for monitoring therapeutic responses, detecting recurrence, and personalizing cancer management in real time, marking the beginning of a new era in precision oncology. Keywords Cancer, Monitoring, Biomarkers, Treatment resistance, Therapy response, Liquid biopsy, Non coding RNAs, lncRNAs, miRNAs, circRNAs  \n\n| †Manon Chang and Thomas Papazyan contributed equally to this work. |\n| --- |\n| †Elvire Pons-Tostivint and Delphine Fradin contributed equally to this work. |\n\n*Correspondence: Delphine Fradin  \ndelphine.fradin@inserm.fr  \n1Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d’Angers, CRCI2NA, Nantes, France  \n2Department of Medical Oncology, University Hospital of Nantes, Nantes, France  \nBackground  \nSince the advent of precision medicine in solid oncology, which aims to propose personalized therapies based on individual molecular characteristics, patient outcomes have improved significantly. However, despite continuous innovations in the therapeutic arsenal of solid oncology, many patients still do not benefit from current treatments. In this context, biomarkers are valuable and promising tools to enhance therapeutic guidance and improve clinical outcomes. Biomarkers are molecules (such as proteins, metabolites, RNA, DNA, genomic alterations…) by which a disease can be easily identified, or by which its evolution can be tracked. They can be detected in tissues, or in biological fluid samples where they are called liquid biomarkers. Biomarkers can be used to detect the early onset of cancer in families with  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati","cbCaifItLxRF89do","https://ap.wps.com/l/cbCaifItLxRF89do","pdf",2822498,27,"English","# Abstract\n# Background\n## Biomarkers and liquid biomarkers\n## Clinical requirements for biomarkers","[{\"question\":\"Why are non-coding RNAs considered promising biomarkers in precision oncology?\",\"answer\":\"Non-coding RNAs such as microRNAs, long non-coding RNAs, and circular RNAs are highlighted because they are stable in body fluids and dynamically change in response to treatment. This supports their use as informative biomarkers for monitoring cancer over time.\"},{\"question\":\"How do liquid biopsies improve therapeutic guidance compared with traditional approaches?\",\"answer\":\"The text emphasizes that biomarkers measurable in non-invasive liquid biopsies can enable more effective and dynamic therapeutic strategies. It contrasts the limitations of circulating tumor DNA in capturing tumor complexity with the broader biological insight provided by ncRNAs.\"},{\"question\":\"What key characteristics must clinically useful biomarkers have?\",\"answer\":\"Clinically valuable biomarkers should be safe, easy, and cost-effective to measure, preferably non-invasively, with high sensitivity and high specificity. They should also show strong positive and negative predictive values for the intended outcome.\"}]","Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology | PDF",1790061597,68,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b5c3ddcb07afc1dc4831bd810cb1e005.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/042634b1711b39eee60500dc8faa460f.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/557784b45dfeb5efc866505605c3d8ed.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83f802aff656110f49b10310d3a12b54.webp",980,1306]